Cargando…

Absence of Bcl-2 and Fas/CD95/APO-1 predicts the response to immunotherapy in metastatic renal cell carcinoma

Immunotherapy is the only available treatment for metastatic renal cell cancer (RCC), but the response rate is only about 20% and the treatment is occasionally associated with severe adverse effects. Thus, the selection of patients with a high susceptibility to immunotherapy is needed; however, ther...

Descripción completa

Detalles Bibliográficos
Autores principales:	Maruyama, R, Yamana, K, Itoi, T, Hara, N, Bilim, V, Nishiyama, T, Takahashi, K, Tomita, Y
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2006
Materias:	Molecular Diagnostics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360577/ https://www.ncbi.nlm.nih.gov/pubmed/17031406 http://dx.doi.org/10.1038/sj.bjc.6603359

Ejemplares similares

Prognostic impact of FAS/CD95/APO-1 in urothelial cancers: decreased expression of Fas is associated with disease progression
por: Yamana, K, et al.
Publicado: (2005)

Impact of frequent Bcl-2 expression on better prognosis in renal cell carcinoma patients
por: Itoi, T, et al.
Publicado: (2004)

Significance of serum-soluble CD95 (Fas/APO-1) on prognosis in renal cell cancer patients
por: Kimura, M, et al.
Publicado: (1999)

Prognostic significance of Bcl-xL expression and efficacy of Bcl-xL targeting therapy in urothelial carcinoma
por: Yoshimine, S, et al.
Publicado: (2013)

An antiapoptotic Bcl-2 family protein index predicts the response of leukaemic cells to the pan-Bcl-2 inhibitor S1
por: Zhang, Z, et al.
Publicado: (2013)

Prostaglandin E(2) stimulates Fas ligand expression via the EP1 receptor in colon cancer cells
por: O'Callaghan, G, et al.
Publicado: (2008)

Bcl-2 expression predicts radiotherapy failure in laryngeal cancer
por: Nix, P, et al.
Publicado: (2005)

Bcl-2 expression in rituximab refractory cutaneous B-cell lymphoma
por: Wobser, M, et al.
Publicado: (2007)

Signaling through the Death Receptor CD95 (APO-1/FAS)
por: Peter, Marcus E.
Publicado: (2001)

BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received
por: Dawson, S-J, et al.
Publicado: (2010)

Serum levels of hepatocyte growth factor and epiregulin are associated with the prognosis on anti-EGFR antibody treatment in KRAS wild-type metastatic colorectal cancer
por: Takahashi, N, et al.
Publicado: (2014)

Nicotine increases the resistance of lung cancer cells to cisplatin through enhancing Bcl-2 stability
por: Nishioka, T, et al.
Publicado: (2014)

Absence of a specific radiation signature in post-Chernobyl thyroid cancers
por: Detours, V, et al.
Publicado: (2005)

KRAS mutations in primary tumours and post-FOLFOX metastatic lesions in cases of colorectal cancer
por: Kawamoto, Y, et al.
Publicado: (2012)

Bicalutamide-induced hypoxia potentiates RUNX2-mediated Bcl-2 expression resulting in apoptosis resistance
por: Browne, G, et al.
Publicado: (2012)

Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage
Publicado: (1995)

Bcl-2 and β(1)-integrin predict survival in a tissue microarray of small cell lung cancer
por: Lawson, M H, et al.
Publicado: (2010)

Absence of p300 induces cellular phenotypic changes characteristic of epithelial to mesenchyme transition
por: Krubasik, D, et al.
Publicado: (2006)

IL-22 produced by cancer-associated fibroblasts promotes gastric cancer cell invasion via STAT3 and ERK signaling
por: Fukui, H, et al.
Publicado: (2014)

Endo180 modulation by bisphosphonates and diagnostic accuracy in metastatic breast cancer
por: Palmieri, C, et al.
Publicado: (2013)

Sentinel node lymphocytes: tumour reactive lymphocytes identified intraoperatively for the use in immunotherapy of colon cancer
por: Marits, P, et al.
Publicado: (2006)

Hyponatremia as a prognostic and predictive factor in metastatic renal cell carcinoma
por: Jeppesen, A N, et al.
Publicado: (2010)

Absence of the DNA repair enzyme human 8-oxoguanine glycosylase is associated with an aggressive breast cancer phenotype
por: Karihtala, P, et al.
Publicado: (2012)

BCL6 degradation caused by the interaction with the C-terminus of pro-HB-EGF induces cyclin D2 expression in gastric cancers
por: Hirata, Y, et al.
Publicado: (2009)

Hepatitis C virus positive diffuse large B-cell lymphomas have distinct molecular features and lack BCL2 translocations
por: Visco, Carlo, et al.
Publicado: (2017)

Inhibition of neurotensin receptor 1 induces intrinsic apoptosis via let-7a-3p/Bcl-w axis in glioblastoma
por: Dong, Zhen, et al.
Publicado: (2017)

Annexin II represents metastatic potential in clear-cell renal cell carcinoma
por: Ohno, Y, et al.
Publicado: (2009)

Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer
por: Chua, W, et al.
Publicado: (2009)

HIF-1α determines the metastatic potential of gastric cancer cells
por: Rohwer, N, et al.
Publicado: (2009)

Methylation levels of LINE-1 in primary lesion and matched metastatic lesions of colorectal cancer
por: Murata, A, et al.
Publicado: (2013)

PI3K/Akt signalling is required for the attachment and spreading, and growth in vivo of metastatic scirrhous gastric carcinoma
por: Matsuoka, T, et al.
Publicado: (2012)

Apoptotic signaling through CD95 (Fas/Apo-1) activates an acidic sphingomyelinase
Publicado: (1994)

Down-regulation of frizzled-7 expression decreases survival, invasion and metastatic capabilities of colon cancer cells
por: Ueno, K, et al.
Publicado: (2009)

Double inhibition of XIAP and Bcl-2 axis is beneficial for retrieving sensitivity of renal cell cancer to apoptosis
por: Bilim, V, et al.
Publicado: (2008)

Absence of VHL gene alteration and high VEGF expression are associated with tumour aggressiveness and poor survival of renal-cell carcinoma
por: Patard, J-J, et al.
Publicado: (2009)

KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer
por: Spindler, K G, et al.
Publicado: (2013)

Restriction of GAGE protein expression to subpopulations of cancer cells is independent of genotype and may limit the use of GAGE proteins as targets for cancer immunotherapy
por: Gjerstorff, M F, et al.
Publicado: (2006)

Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease
por: Zidan, J, et al.
Publicado: (2005)

Identification of claudin-4 as a marker highly overexpressed in both primary and metastatic prostate cancer
por: Landers, K A, et al.
Publicado: (2008)

Relationship of increased aurora kinase A gene copy number, prognosis and response to chemotherapy in patients with metastatic colorectal cancer
por: Dotan, E, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_514bfb2hm13bn0hj2ndduqnr7f